2Q EARNINGS: J&J flaunts pharma future; investors wary
This article was originally published in Scrip
Investors obsessed over the spike in Johnson & Johnson's Olysio (simeprevir) sales – from $354m in the first quarter to $831m in the second – and an expected slump later this year due to new competition in hepatitis C, despite the company's message on 15 July about its pharmaceutical future.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.